PRESERVE WHAT MATTERS TO YOUR CHILD AFFECTED BY DUCHENNE MUSCULAR DYSTROPHY

It’s time for more moments that matter. It’s time to consider EMFLAZA®, the first and only corticosteroid FDA-approved for the treatment of Duchenne muscular dystrophy

This the group background image

In a clinical trial of 196 boys aged 5 to 15 with Duchenne muscular dystrophy, the effectiveness and safety of EMFLAZA were compared with placebo (sugar pills)

EMFLAZA improved muscle strength at 12 weeks compared with placebo

This the group background image

EMFLAZA was numerically favored in timed measures of patient function in comparison with placebo

Time to
stand up

Time to
walk 30 feet

Time to
climb 4 stairs

These findings were not considered statistically significant. This means that because the two groups studied were not large enough, the results could have occurred by chance.